Currently, serological tumor biomarkers such as carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) have been clinically used for the detection of many cancers including CRC (5, 6), yet with low specificity (7–9). This evidence concerns the gene CEACAM5 and cancer.